In our study, we showed that CBX7 acted as a glioma suppressor via G1/S arrest. First, we analyzed CBX7 mRNA levels and patient outcomes in four public databases including CGGA, TCGA, REMBRANDT and GSE16011 databases. In all cohorts, the expression of CBX7 was significantly lower in HGG compared with LGG or NBT. The result showed that there was a significant inverse correlation between CBX7 level and glioma grade. In addition, survival analysis portrayed CBX7 as a valuable biomarker in survival prediction because the reduced expression of CBX7 correlated with poor outcome in HGG patients.